Previous 10 | Next 10 |
Invitae Introduces First Comprehensive Genetic Test Suite for Neurodevelopmental Disorders PR Newswire – First to offer suite of tests in easy to access format for children with developmental disabilities – SAN FRANCISCO , April 4, 2022 ...
ETF has found a way to generate some fresh capital for purchases. Seven names have been sold but don't appear in the daily e-mail. Cathie Wood's tweet doesn't match this reality. For further details see: ARKK: Cathie Wood's Secret Selling
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
The field of genetics is the new scientific frontier. Genetic testing, in particular, could one day play a vital role in how we understand, prevent, and treat disease. Invitae (NYSE: NVTA) has been at the forefront of the industry for years. However, investors who bought at the ...
Introducing Invitae Digital Health--A Personalized Health Management Platform That Leverages Genomic Insights to Inform Health Decisions for Patients and Clinicians PR Newswire – Invitae launches seamless digital platform to enhance patient and provider experience...
Shares of molecular diagnostics company Invitae (NYSE: NVTA) climbed 10.7% on Tuesday. The company closed at $7.96 on Monday, then, after opening at $7.90 on Tuesday, climbed as high as $8.81 shortly after 11 a.m. ET. The stock is down more than 43% this year and it has a 52-week lo...
The bloodbath for Cathie Wood’s ARK Innovation ETF (NYSEARCA:ARKK) continues, despite the fund being up slightly on Thursday. Wood’s ETF is -36% YTD and is currently working towards its fifth straight downward month. Meanwhile, this week has been particularly difficult...
Invitae Launches Full Access to its Liquid-Based Personalized Cancer Monitoring Platform to Help Detect Disease Earlier PR Newswire – Personalized tumor-informed assay helps patients get ahead of cancer – SAN FRANCISCO , March 17, 2022 ...
Invitae Publishes the 2022 Environmental, Social and Governance Report PR Newswire – Report details the company's dedication to healthcare for humanity through sustainable practices coupled with progress towards its mission – SAN FRANCISCO ,...
The Ark Innovation ETF was fallen 60% from its high water mark, far more than 10%ish drop of the handful of growth stocks which top the S&P 500 and NASDAQ100. Charts and tables for price and AUM show clearly the the majority of investors in ARKK bought at the top; most ARKK holder...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...